Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review
Chengyuan Liang, Danni Tian, Xiaodong Ren, et al.
European Journal of Medicinal Chemistry (2018) Vol. 151, pp. 315-326
Closed Access | Times Cited: 155

Showing 26-50 of 155 citing articles:

Bruton’s Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy
Antonio Garcı́a-Merino
Cells (2021) Vol. 10, Iss. 10, pp. 2560-2560
Open Access | Times Cited: 41
Multiple Sclerosis Pathogenesis and Updates in Targeted Therapeutic Approaches
Eleni S. Vasileiou, Kathryn C. Fitzgerald
Current Allergy and Asthma Reports (2023) Vol. 23, Iss. 9, pp. 481-496
Closed Access | Times Cited: 19
Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL)
Alexandra Chirino, Skye Montoya, Anita Safronenka, et al.
Genes (2023) Vol. 14, Iss. 12, pp. 2182-2182
Open Access | Times Cited: 19
Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia
Skye Montoya, Meghan C. Thompson
Cancers (2023) Vol. 15, Iss. 14, pp. 3648-3648
Open Access | Times Cited: 18
Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes
Jithma P. Abeykoon, Saurabh Zanwar, Stephen M. Ansell, et al.
British Journal of Haematology (2019) Vol. 188, Iss. 3, pp. 394-403
Open Access | Times Cited: 47
Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations
Xiaoyun Lu, Jeff B. Smaill, Ke Ding
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 19, pp. 10726-10741
Closed Access | Times Cited: 43
A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors
Phillip L. R. Nicolson, John D. Welsh, Abhishek Chauhan, et al.
Platelets (2020) Vol. 31, Iss. 5, pp. 685-690
Open Access | Times Cited: 42
Bruton’s tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis
Edgar Carnero Contentti, Jorge Correale
Expert Opinion on Emerging Drugs (2020) Vol. 25, Iss. 4, pp. 377-381
Open Access | Times Cited: 42
Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease
Stefan F. H. Neys, Jasper Rip, Rudi W. Hendriks, et al.
Drugs (2021) Vol. 81, Iss. 14, pp. 1605-1626
Open Access | Times Cited: 40
The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015–2020
Xiaoxia Liang, Qian Yang, Pan Wu, et al.
Bioorganic Chemistry (2021) Vol. 113, pp. 105011-105011
Closed Access | Times Cited: 37
Inflammasome activation controlled by the interplay between post-translational modifications: emerging drug target opportunities
Zhu Liang, Andreas Damianou, Elena Di Daniel, et al.
Cell Communication and Signaling (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 35
Progress in the development of small molecular inhibitors of the Bruton’s tyrosine kinase (BTK) as a promising cancer therapy
Xiujuan Liu, Xu-Liu, Xiaojing Pang, et al.
Bioorganic & Medicinal Chemistry (2021) Vol. 47, pp. 116358-116358
Closed Access | Times Cited: 33
Medicinal Chemistry Strategies for the Development of Bruton’s Tyrosine Kinase Inhibitors against Resistance
Shan‐Liang Sun, Shi-Han Wu, Ji-Bo Kang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7415-7437
Closed Access | Times Cited: 27
New drugs for multiple sclerosis: new treatment algorithms
Bruce Cree, Hans‐Peter Hartung, Michael Barnett
Current Opinion in Neurology (2022) Vol. 35, Iss. 3, pp. 262-270
Open Access | Times Cited: 27
Universal Approach to De Novo Drug Design for Target Proteins Using Deep Reinforcement Learning
Yunjiang Zhang, Shuyuan Li, Miaojuan Xing, et al.
ACS Omega (2023) Vol. 8, Iss. 6, pp. 5464-5474
Open Access | Times Cited: 15
A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis
Laura Airas, Robert Bermel, Tanuja Chitnis, et al.
Therapeutic Advances in Neurological Disorders (2024) Vol. 17
Open Access | Times Cited: 5
The preclinical discovery and development of zanubrutinib for the treatment of chronic lymphocytic leukemia
Tina Schleicher, Melanie Cohen, Solomon A. Graf
Expert Opinion on Drug Discovery (2025)
Closed Access
A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
Chandrakant Gawli, Chandragouda R. Patil, Harun Patel
Bioorganic & Medicinal Chemistry (2025) Vol. 123, pp. 118146-118146
Closed Access
Triazol: A Privileged Scaffold for Proteolysis Targeting Chimeras
Liwen Xia, Meng-Yu Ba, Wei Liu, et al.
Future Medicinal Chemistry (2019) Vol. 11, Iss. 22, pp. 2919-2973
Closed Access | Times Cited: 39
Recent Advances in c-Jun N-Terminal Kinase (JNK) Inhibitors
Gang Li, Wenqing Qi, Xiaoxun Li, et al.
Current Medicinal Chemistry (2020) Vol. 28, Iss. 3, pp. 607-627
Closed Access | Times Cited: 33
Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function
Tony J. Zheng, Elizabeth R. Lofurno, Alexander R. Melrose, et al.
AJP Cell Physiology (2021) Vol. 320, Iss. 5, pp. C902-C915
Open Access | Times Cited: 32
If small molecules immunotherapy comes, can the prime be far behind?
Jingyu Zhang, Yu Zhang, Bingxue Qu, et al.
European Journal of Medicinal Chemistry (2021) Vol. 218, pp. 113356-113356
Closed Access | Times Cited: 29
Novel therapies for immune thrombocytopenia
David J. Kuter
British Journal of Haematology (2021) Vol. 196, Iss. 6, pp. 1311-1328
Open Access | Times Cited: 28
Recent development of BTK-based dual inhibitors in the treatment of cancers
Fansheng Ran, Yun Liu, Zhongyuan Xu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 233, pp. 114232-114232
Closed Access | Times Cited: 21
Regulation of the Tec family of non-receptor tyrosine kinases in cardiovascular disease
Zeyu Yin, Yuanming Zou, Dong Wang, et al.
Cell Death Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 20

Scroll to top